In Re: Purdue Pharma L.P.

  1. May 30, 2023

    2nd Circ. Upholds Sackler Releases In Purdue Ch. 11 Plan

    The Second Circuit on Tuesday upheld the provisions of Purdue Pharma's Chapter 11 plan, releasing its former owners in the Sackler family from liability for damages stemming from the opioid addiction epidemic, finding the releases were both legal and justified.

  2. January 02, 2023

    Bankruptcy Cases And Trends To Watch In 2023

    The last quarter of 2022 saw a wave of cryptocurrency cases hit bankruptcy courts, with industry giant FTX Trading kicking off a period of distress for the industry, and bankruptcy experts say those troubles are just beginning.

  3. April 29, 2022

    Purdue Tells 2nd Circ. 30 Years Of Precedent Back Ch. 11 Plan

    Attorneys for Purdue Pharma LP defended the company's Chapter 11 plan Friday to the Second Circuit, arguing that more than three decades of case law in the circuit permits the releases in the plan that extinguish third-party claims against the members of the Sackler family that own Purdue.

  4. April 15, 2022

    Newborn Opioid Victim Group Says Sackler Releases Justified

    A group representing victims of neonatal abstinence syndrome has told the Second Circuit that the benefits those victims will get under opioid maker Purdue Pharma's Chapter 11 plan are large enough to justify the releases that the plan grants Purdue's former owners.

  5. April 06, 2022

    US Trustee Urges 2nd Circ. To Reject Sackler Opioid Releases

    The U.S. Trustee's Office is urging the Second Circuit to uphold a finding that Purdue Pharma's former owners in the Sackler family cannot be released from opioid liability by the company's Chapter 11 plan, saying it would violate a "keystone" of bankruptcy law.

  6. March 25, 2022

    Sacklers Say New Ch. 11 Plan Boasts 'Extraordinary' Support

    The Sackler family said Friday that Purdue's newly negotiated Chapter 11 plan "reflects an extraordinary consensus" and urged the Second Circuit to reject appeals challenging the family's nonconsensual third-party releases, which the Sacklers said are integral to the plan's success.